EcoDrugPlus

Solute Carrier Family 6 Member 4a

Ensembl ID : ENSDARG00000061165
Gene Symbol: SLC6A4A
4 Enzyme and pathways 5 Cross references
203 Possible Orthologues:

Solute Carrier Family 6 Member 9

Ensembl ID : ENSDARG00000018534
Gene Symbol: SLC6A9
4 Enzyme and pathways 5 Cross references
207 Possible Orthologues:

Solute Carrier Family 9 Member A3, Tandem Duplicate 1

Ensembl ID : ENSDARG00000058498
Gene Symbol: SLC9A3.1
5 Cross references
231 Possible Orthologues:

Solute Carrier Family 9 Member A3, Tandem Duplicate 2

Ensembl ID : ENSDARG00000036722
Gene Symbol: SLC9A3.2
4 Enzyme and pathways 5 Cross references
230 Possible Orthologues:

Somatostatin Receptor 1a

Ensembl ID : ENSDARG00000104922
Gene Symbol: SSTR1A
7 Enzyme and pathways 5 Cross references
160 Possible Orthologues:

Somatostatin Receptor 2a

Ensembl ID : ENSDARG00000059090
Gene Symbol: SSTR2A
7 Enzyme and pathways 5 Cross references
192 Possible Orthologues:

Somatostatin Receptor 2b

Ensembl ID : ENSDARG00000069806
Gene Symbol: SSTR2B
5 Cross references
192 Possible Orthologues:

Somatostatin Receptor 3

Ensembl ID : ENSDARG00000014477
Gene Symbol: SSTR3
11 Enzyme and pathways 5 Cross references
187 Possible Orthologues:

Sphingosine Kinase 2

Ensembl ID : ENSDARG00000069893
Gene Symbol: SPHK2
4 Enzyme and pathways 5 Cross references
203 Possible Orthologues:

Sphingosine-1-Phosphate Receptor 1

Ensembl ID : ENSDARG00000042690
Gene Symbol: S1PR1
7 Enzyme and pathways 5 Cross references
193 Possible Orthologues:

Spleen Tyrosine Kinase

Ensembl ID : ENSDARG00000008186
Gene Symbol: SYK
26 Enzyme and pathways 5 Cross references
203 Possible Orthologues:

Steroid-5-Alpha-Reductase, Alpha Polypeptide 2a

Ensembl ID : ENSDARG00000043587
Gene Symbol: SRD5A2A
5 Enzyme and pathways 5 Cross references
208 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).